Relay Therapeutics (RLAY) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$91.6 million.
- Relay Therapeutics' Enterprise Value rose 3990.17% to -$91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.6 million, marking a year-over-year increase of 3990.17%. This contributed to the annual value of -$124.3 million for FY2024, which is 1353.11% up from last year.
- According to the latest figures from Q3 2025, Relay Therapeutics' Enterprise Value is -$91.6 million, which was up 3990.17% from -$113.9 million recorded in Q2 2025.
- Over the past 5 years, Relay Therapeutics' Enterprise Value peaked at -$91.6 million during Q3 2025, and registered a low of -$354.6 million during Q3 2022.
- Over the past 5 years, Relay Therapeutics' median Enterprise Value value was -$151.3 million (recorded in 2023), while the average stood at -$170.0 million.
- Over the last 5 years, Relay Therapeutics' Enterprise Value had its largest YoY gain of 5913.35% in 2021, and its largest YoY loss of 27348.95% in 2021.
- Quarter analysis of 5 years shows Relay Therapeutics' Enterprise Value stood at -$280.1 million in 2021, then surged by 45.81% to -$151.8 million in 2022, then increased by 5.31% to -$143.7 million in 2023, then grew by 13.53% to -$124.3 million in 2024, then grew by 26.33% to -$91.6 million in 2025.
- Its Enterprise Value stands at -$91.6 million for Q3 2025, versus -$113.9 million for Q2 2025 and -$93.5 million for Q1 2025.